143 related articles for article (PubMed ID: 16719821)
21. Combination therapy with lamivudine and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker for hepatitis B virus-associated glomerulonephritis with mild to moderate proteinuria: a clinical review of 38 cases.
Sun LJ; Shan JP; Cui RL; Yuan WJ; Jiang GR
Int Urol Nephrol; 2017 Jun; 49(6):1049-1056. PubMed ID: 28283858
[TBL] [Abstract][Full Text] [Related]
22. [Renin-angiotensin-aldosterone system inhibition: pharmacologic rationale and evaluations of drug combinations].
Andréjak M; Slama M; Hary L
Therapie; 1998; 53(3):291-300. PubMed ID: 9773129
[TBL] [Abstract][Full Text] [Related]
23. Clinical inquiries. Which combination drug therapies are most effective for hypertension?
Crawford P; Dy D; Carney M
J Fam Pract; 2011 Nov; 60(11):684-6. PubMed ID: 22049354
[TBL] [Abstract][Full Text] [Related]
24. Renin-angiotensin system blockers and residual kidney function loss in patients initiating peritoneal dialysis: an observational cohort study.
Shen JI; Saxena AB; Vangala S; Dhaliwal SK; Winkelmayer WC
BMC Nephrol; 2017 Jun; 18(1):196. PubMed ID: 28623899
[TBL] [Abstract][Full Text] [Related]
25. [Angiotensin II receptor blockers--evidence along the cardiovascular continuum].
Zeller A; Battegay E
Praxis (Bern 1994); 2005 Apr; 94(15):581-94. PubMed ID: 15884724
[TBL] [Abstract][Full Text] [Related]
26. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure.
Jorde UP; Ennezat PV; Lisker J; Suryadevara V; Infeld J; Cukon S; Hammer A; Sonnenblick EH; Le Jemtel TH
Circulation; 2000 Feb; 101(8):844-6. PubMed ID: 10694521
[TBL] [Abstract][Full Text] [Related]
27. Low body mass index is a risk factor for hyperkalaemia associated with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers treatments.
Hirai T; Yamaga R; Fujita A; Itoh T
J Clin Pharm Ther; 2018 Dec; 43(6):829-835. PubMed ID: 29908131
[TBL] [Abstract][Full Text] [Related]
28. The reno-protective effect of the dual blockade of the renin angiotensin system (RAS).
Luno J; Praga M; de Vinuesa SG
Curr Pharm Des; 2005; 11(10):1291-300. PubMed ID: 15853685
[TBL] [Abstract][Full Text] [Related]
29. Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade.
Ferrari P; Marti HP; Pfister M; Frey FJ
J Hypertens; 2002 Jan; 20(1):125-30. PubMed ID: 11791035
[TBL] [Abstract][Full Text] [Related]
30. A review of chemical therapies for treating diabetic hypertension.
Sarafidis PA; Alexandrou ME; Ruilope LM
Expert Opin Pharmacother; 2017 Jun; 18(9):909-923. PubMed ID: 28480805
[TBL] [Abstract][Full Text] [Related]
31. Combined therapy of cilazapril and losartan has no additive effects in ameliorating adriamycin-induced glomerulopathy.
Kim HJ; Ryu JH; Han SW; Park IK; Paik SS; Park MH; Paik DJ; Chung HS; Kim SW; Lee JU
Nephron Physiol; 2004; 97(4):p58-65. PubMed ID: 15331931
[TBL] [Abstract][Full Text] [Related]
32. Renin-angiotensin-aldosterone inhibitors in the reduction of portal pressure: a systematic review and meta-analysis.
Tandon P; Abraldes JG; Berzigotti A; Garcia-Pagan JC; Bosch J
J Hepatol; 2010 Aug; 53(2):273-82. PubMed ID: 20570385
[TBL] [Abstract][Full Text] [Related]
33. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data.
MacKinnon M; Shurraw S; Akbari A; Knoll GA; Jaffey J; Clark HD
Am J Kidney Dis; 2006 Jul; 48(1):8-20. PubMed ID: 16797382
[TBL] [Abstract][Full Text] [Related]
34. Improved persistence and adherence to diuretic fixed-dose combination therapy compared to diuretic monotherapy.
Patel BV; Remigio-Baker RA; Thiebaud P; Preblick R; Plauschinat C
BMC Fam Pract; 2008 Nov; 9():61. PubMed ID: 18990240
[TBL] [Abstract][Full Text] [Related]
35. Impact of an intervention on the prescription of aliskiren after new evidence on safety reported.
Rosich Martí I; Allepuz A; Rodriguez Palomar G; Ortin Font F; Soler Cera M
Pharmacoepidemiol Drug Saf; 2017 Jan; 26(1):91-96. PubMed ID: 27859873
[TBL] [Abstract][Full Text] [Related]
36. A comparison between angiotensin converting enzyme inhibitors and angiotensin receptor blockers on end stage renal disease and major adverse cardiovascular events in diabetic patients: a population-based dynamic cohort study in Taiwan.
Wu LS; Chang SH; Chang GJ; Liu JR; Chan YH; Lee HF; Wen MS; Chen WJ; Yeh YH; Kuo CT; See LC
Cardiovasc Diabetol; 2016 Apr; 15():56. PubMed ID: 27039185
[TBL] [Abstract][Full Text] [Related]
37. Resistant Hypertension On Treatment (ResHypOT): sequential nephron blockade compared to dual blockade of the renin-angiotensin-aldosterone system plus bisoprolol in the treatment of resistant arterial hypertension - study protocol for a randomized controlled trial.
Cestário EDES; Fernandes LAB; Giollo-Júnior LT; Uyemura JRR; Matarucco CSS; Landim MIP; Cosenso-Martin LN; Tácito LHB; Moreno H; Vilela-Martin JF; Yugar-Toledo JC
Trials; 2018 Feb; 19(1):101. PubMed ID: 29433578
[TBL] [Abstract][Full Text] [Related]
38. Antihypertensive treatment and risk of atrial fibrillation: a nationwide study.
Marott SC; Nielsen SF; Benn M; Nordestgaard BG
Eur Heart J; 2014 May; 35(18):1205-14. PubMed ID: 24347316
[TBL] [Abstract][Full Text] [Related]
39. Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial.
Rossing K; Jacobsen P; Pietraszek L; Parving HH
Diabetes Care; 2003 Aug; 26(8):2268-74. PubMed ID: 12882847
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness of angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker on atrial natriuretic peptide.
Sata N; Tanaka Y; Suzuki S; Kamimura R; Mifune H; Nakamura K; Miyahara K; Arima T
Circ J; 2003 Dec; 67(12):1053-8. PubMed ID: 14639023
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
